It is a link for moving within the page.

Go to the main.
Go to the global navigation.
Go to navigation by category.
Go to the footer.

News ReleasesNews releases related to tuberculosis

2020

25 MAY 2020Pharmaceuticals: Deltyba^® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)

27 FEB 2020Pharmaceuticals: First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis

2018

23 MAR 2018Pharmaceuticals: Otsuka's DELTYBA Approved in China for the Treatment of Multidrug-resistant Tuberculosis

29 JAN 2018Pharmaceuticals: Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid

2017

14 DEC 2017Pharmaceuticals: Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time

24 AUG 2017Pharmaceuticals: Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF:467.1 KB)

18 JUL 2017Pharmaceuticals: Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF:99.9 KB)

1 JUN 2017Pharmaceuticals: Otsuka to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)

2016

21 APR 2016Pharmaceuticals: Otsuka receives two commendations by the Japanese Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment

25 FEB 2016Pharmaceuticals: Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility

2015

7 DEC 2015Pharmaceuticals: Winner Announced for the 2015 Young Innovator in TB Research Award

16 JUL 2015Pharmaceuticals: Efficacy Results of Otsuka's Delamanid (Deltyba^™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine

19 MAR 2015Pharmaceuticals: The Union and Otsuka Open Nominations for 2^nd Global TB Research & Innovation Award

2014

8 SEP 2014Pharmaceuticals: A Change in the Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba^® in 50 mg Tablets, Available to Patients in Japan Starting September 26

4 JUL 2014Pharmaceuticals: After 40 Years, A New Drug For The Treatment Of Tuberculosis In Japan Deltyba^® (delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)

30 APR 2014Pharmaceuticals: Otsuka Wins European Marketing Authorization for Deltyba^™ (delamanid)

2013

25 NOV 2013Pharmaceuticals: CHMP Recommends Otsuka's Deltyba^™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)

27 MAR 2013Pharmaceuticals: Otsuka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis

2012

7 JUN 2012Pharmaceuticals: The New England Journal of Medicine Publishes Efficacy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months

2011

17 MAY 2011Pharmaceuticals: Otsuka Pharmaceutical Establishes Subsidiary, Otsuka SA, to Facilitate Public Advocacy for the Company's Global Tuberculosis Program